CliffBio
biologic

Winrevair

sotatercept-csrk

Loss of exclusivityMarch 2036projected — 12-year biologic exclusivity estimate
CompanyMerck Sharp & Dohme LLC

Drug detail

Brand nameWinrevair
Active ingredientsotatercept-csrk
Strength45MG
Dosage formFor Injection
RouteSubcutaneous
ModalityBiologic
FDA approvalMarch 2024
Marketing statusRx

More from Merck Sharp & Dohme LLC

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Winrevair patent cliff — loss of exclusivity March 2036 | CliffBio